Gabelli Funds LLC Acquires New Position in Drugs Made In America Acquisition II Corp. $DMII

Gabelli Funds LLC acquired a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 161,400 shares of the company’s stock, valued at approximately $1,609,000.

Other large investors also recently bought and sold shares of the company. Geode Capital Management LLC bought a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $265,000. Virtu Financial LLC bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at approximately $317,000. ABC Arbitrage SA bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at approximately $396,000. Deltec Asset Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter valued at approximately $495,000. Finally, Royal Bank of Canada acquired a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter valued at approximately $655,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DMII shares. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Drugs Made In America Acquisition II presently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Trading Up 0.1%

Shares of NASDAQ DMII opened at $10.12 on Thursday. The stock has a 50-day simple moving average of $10.08. Drugs Made In America Acquisition II Corp. has a 52-week low of $9.86 and a 52-week high of $10.20.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.